Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of pegylated interferon alfa-2b + ribavirin + nitazoxanide in HIV/HCV genotype 4 coinfected adults
2010-024336-42Phase 2Active
- Sponsor
- JUAN MACIAS SANCHEZ
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nitazoxanide, peginterferon alfa-2b and ribavirin in chronic hepatitis C (CHC) and human immunodeficiency virus infection (HIV), sponsored by JUAN MACIAS SANCHEZ. Primary endpoint: Sustained virologic response. Started Dec 2010; status: active.
02
Drugs
nitazoxanidepeginterferon alfa-2bribavirin
03
Conditions
chronic hepatitis C (CHC)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-024336-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024336-42.